The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.
Pfizer and BioNTech Sued for Patent Infringement Over mRNA Vaccine Read More »
Parth Mehrotra will succeed Shawn Morris, who led the company through its 2021 initial public offering.
The analysts are “leaning into increased medtech exposure” after determining that several challenges that have constrained the industry are easing.
Medtech sector poised for growth as healthcare staffing tops pre-COVID levels: KeyBanc Read More »
The company has several targeted therapeutics in early-stage trials and preclinical development for cancer types with high expression levels of the protein.
Alentis Wins $105M in Series C to Advance Claudin-1-Based Therapies Read More »
People who used an over-the-counter hearing aid for six weeks saw similar results to people who used an audiologist-fitted device, suggesting less costly, self-fitted hearing aids could be an option.
OTC hearing aid matches performance of audiologist-fitted device in small trial Read More »
Liver toxicities triggered a partial clinical hold on Merck’s trial studying its BTK inhibitor candidate for multiple sclerosis.
Merck’s BTK Inhibitor Evobrutinib Slapped with Partial Clinical Hold Read More »
ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.
ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »
La deficiencia de la tirosina hidroxilasa (THD) es una enfermedad genética ultrarrara que afecta a los niños. Esta enfermedad causa una disminución importante de la dopamina —uno de los neurotransmisores más importantes del sistema nervioso central— en el cere …
En el mundo actual, donde todo ocurre a un ritmo vertiginoso, estar conectado es más importante que nunca. Ya sea que trabaje de forma remota, se mantenga en contacto con amigos y familiares o simplemente navegue por la web, necesita un teléfono con impresionantes capacidades …
Merck announced the U.S. FDA has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
